Brian Buntz is a journalist at Medical Design & Outsourcing. He covers a range of topics within medicine and healthcare, focusing on healthcare technology, artificial intelligence, and machine learning. His work has been featured in notable publications such as TED Conferences, MassDevice, and Pharmaceutical Processing World.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Brian Buntz's articles primarily focus on the healthcare and pharmaceutical industry, with a strong emphasis on data-driven insights. His coverage suggests an interest in topics such as pharmaceutical innovation, M&A activity, emerging trends in drug approvals, and AI applications within healthcare.
Given his reliance on citing data and press releases, Brian may be interested in pitches that provide comprehensive data analysis or newsworthy findings related to pharmaceuticals, medical research advancements, or trends in healthcare technology. Additionally, he might be open to receiving press releases announcing significant developments within the healthcare and pharmaceutical sectors.
While Brian's geographic focus is not specified, his coverage appears to encompass global perspectives on the healthcare and pharmaceutical industry. Therefore, relevant pitches should consider international implications or broader industry trends rather than focusing solely on specific regional matters unless they have global significance.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Brian Buntz
NASA’s standard EMIT methane product (top) and MAPL-EMIT output (bottom) for the same scene. Image: Adapted from Batchu et al., PNAS (2026), CC BY 4.0
| Anthropic's R&D spending has reached the scale of major drugmakers' budgets, extending a trend of tech companies outspending pharma on research and development.
By: Brian Buntz
Jellyfish data from 1,300 companies: agents touch 27.7% of pull requests at the median company, while software factories open 0.0% at nine in 10.
By: Brian Buntz
Anthropic acquired Mithril Medicine, whose sole employee used Claude to run 11 outside labs and reach mouse results for a muscular dystrophy antibody.
| Two cofounders and fewer than 10 employees made up Coefficient Bio, the biology-focused AI startup Anthropic acquired in a deal R&D World
By: Brian Buntz
Nearly seven weeks after announcing an AI-generated proposed solution to the Navier–Stokes problem, and three weeks after releasing hundreds of mathematical manuscripts, OpenAI said on Oct. 26 that its internal AI models have produced three more results addressing longstanding scientific questions.
| Credit: Adobe Stock Clinical trials, defined by meticulous randomization, bias reduction, and causal proof, are often referred to as the gold standard of medical research.
By: Brian Buntz
This website uses cookies We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
By: Brian Buntz
SpaceX is accelerating its shift from rocket company to major AI infrastructure player. Anthropic, the developer of Claude, disclosed in its IPO prospectus that it has agreed to spend up to $120.5 billion on computing capacity from SpaceXAI, SpaceX’s AI subsidiary. The related agreements would extend into 2029 while monthly payments would reach about $3.1 billion once all capacity is delivered, which Anthropic expects in December 2026. A separate Google contract could generate roughly $30 billion for SpaceX through June 2029 for access to approximately 110,000 NVIDIA graphics processing units (GPUs) and supporting equipment.
By: Brian Buntz
Alphabet shares fell 12.6% a day after Google unveiled Gemini 4 Carbon, as Search results and AI spending overshadowed rapid cloud growth.
